Skip to content
lifestyle.spaziotribu.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Amneal Pharmaceuticals LLC
Amneal Announces FDA Approval and Launch of Lanreotide Injection
September 18, 2026
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
August 20, 2026
Amneal Reports Second Quarter 2026 Financial Results
August 19, 2026
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
Amneal to Report Second Quarter 2026 Results on July 30, 2026
July 9, 2026
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
June 29, 2026
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
June 29, 2026
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson’s Disease
June 5, 2026
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
June 4, 2026
1
2
Next Page
→